Stable Cash Flow, New Modalities Key To SK Bio’s Journey To Big, Balanced Biotech

More Acquisitions Eyed After ProteoVant Stake

 
• By Jung Won Shin
  
Donghoon Lee, CEO of SK Biopharmaceuticals
SK Biopharm's CEO Donghoon Lee • Source: SK Biopharmaceuticals

More from Business

More from Scrip